Radical Surgery Compared to Bladder-Preserving Approaches for Limited Stage Small-Cell Bladder Cancer: Systematic Review and Meta-Analysis.

IF 2.7
András Kubik, Isabel Pinto Amorim das Virgens, Nóra Varga, Anett Szabó, Attila Keszthelyi, Péter Fehérvári, Péter Hegyi, Nándor Ács, Péter Nyirády, Tibor Szarvas
{"title":"Radical Surgery Compared to Bladder-Preserving Approaches for Limited Stage Small-Cell Bladder Cancer: Systematic Review and Meta-Analysis.","authors":"András Kubik, Isabel Pinto Amorim das Virgens, Nóra Varga, Anett Szabó, Attila Keszthelyi, Péter Fehérvári, Péter Hegyi, Nándor Ács, Péter Nyirády, Tibor Szarvas","doi":"10.1016/j.clgc.2025.102389","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and objective: </strong>Small-cell bladder cancer (SCBC) is an aggressive and rare malignancy for which there is no clear optimal treatment strategy. This systematic review and meta-analysis aimed to compare the median overall survival (OS) of patients with limited-stage (LS) SCBC treated with either cystectomy-based multimodal therapy (CBMMT) or radiation-based multimodal therapy (RBMMT).</p><p><strong>Methods: </strong>A comprehensive search of PUBMED, Embase, and Scopus databases was performed for studies published before January 2024 according to the PRISMA guidelines. Studies have assessed LS-SCBC disease and provided survival data for subgroups of patients undergoing radical surgery or bladder-preserving approaches to be deemed eligible. Data extraction and quality assessment were independently conducted by 2 authors.</p><p><strong>Key findings and limitations: </strong>Five studies comprising 1041 patients were analyzed. The pooled median OS for patients receiving RBMMT was 34.6 months (95% CI, 25.5-43.7), compared to 29.7 months (95% CI, 18.2-41.1) for those undergoing CBMMT. The main limitations are the retrospective nature of the included studies and the potential bias.</p><p><strong>Conclusions and clinical implications: </strong>This meta-analysis indicates that RBMMT may provide comparable outcomes to CBMMT in LS-SCBC patients, supporting the consideration of bladder-preserving approaches in selected cases. RBMMT may offer a potential clinical benefit in terms of organ preservation for appropriately selected patients, although survival differences were not statistically significant.</p>","PeriodicalId":93941,"journal":{"name":"Clinical genitourinary cancer","volume":" ","pages":"102389"},"PeriodicalIF":2.7000,"publicationDate":"2025-06-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical genitourinary cancer","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.clgc.2025.102389","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background and objective: Small-cell bladder cancer (SCBC) is an aggressive and rare malignancy for which there is no clear optimal treatment strategy. This systematic review and meta-analysis aimed to compare the median overall survival (OS) of patients with limited-stage (LS) SCBC treated with either cystectomy-based multimodal therapy (CBMMT) or radiation-based multimodal therapy (RBMMT).

Methods: A comprehensive search of PUBMED, Embase, and Scopus databases was performed for studies published before January 2024 according to the PRISMA guidelines. Studies have assessed LS-SCBC disease and provided survival data for subgroups of patients undergoing radical surgery or bladder-preserving approaches to be deemed eligible. Data extraction and quality assessment were independently conducted by 2 authors.

Key findings and limitations: Five studies comprising 1041 patients were analyzed. The pooled median OS for patients receiving RBMMT was 34.6 months (95% CI, 25.5-43.7), compared to 29.7 months (95% CI, 18.2-41.1) for those undergoing CBMMT. The main limitations are the retrospective nature of the included studies and the potential bias.

Conclusions and clinical implications: This meta-analysis indicates that RBMMT may provide comparable outcomes to CBMMT in LS-SCBC patients, supporting the consideration of bladder-preserving approaches in selected cases. RBMMT may offer a potential clinical benefit in terms of organ preservation for appropriately selected patients, although survival differences were not statistically significant.

有限期小细胞膀胱癌根治性手术与膀胱保留方法的比较:系统回顾和荟萃分析。
背景和目的:小细胞膀胱癌(SCBC)是一种侵袭性的罕见恶性肿瘤,目前尚无明确的最佳治疗策略。本系统综述和荟萃分析旨在比较以膀胱切除术为基础的多模式治疗(CBMMT)或以放射为基础的多模式治疗(RBMMT)治疗的有限期(LS) SCBC患者的中位总生存期(OS)。方法:根据PRISMA指南,对2024年1月前发表的研究进行PUBMED、Embase和Scopus数据库的综合检索。研究评估了LS-SCBC疾病,并为接受根治性手术或膀胱保留方法的患者亚组提供了生存数据。数据提取和质量评价由2位作者独立完成。主要发现和局限性:分析了包括1041例患者的5项研究。接受RBMMT的患者的总中位OS为34.6个月(95% CI, 25.5-43.7),而接受CBMMT的患者的总中位OS为29.7个月(95% CI, 18.2-41.1)。主要的限制是纳入研究的回顾性性质和潜在的偏倚。结论和临床意义:本荟萃分析表明,在LS-SCBC患者中,RBMMT可能提供与CBMMT相当的结果,支持在选定病例中考虑膀胱保留入路。RBMMT可能在器官保存方面为适当选择的患者提供潜在的临床益处,尽管生存差异没有统计学意义。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信